£2.0M
The seed round was led by XTX Ventures and Prostate Cancer Research to support regulatory approvals and clinical studies.
"We are tremendously excited about the potential of this system to enhance our ability to detect cancer accurately and early. We are now looking forward to working with hospitals and radiology and urology partners to prove the technology and bring it into clinical use. Covid-19 has created a serious backlog in cancer screening and Lucida Medical is well placed to help us clear this and improve the care that we offer further over the coming years."
